Claims for Patent: 7,514,444

Summary for Patent: 7,514,444

Title:	Inhibitors of bruton's tyrosine kinase
Abstract:	Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (San Mateo, CA), Pan; Zhengying (Apharetta, GA)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:	11/617,645
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,514,444
Patent Claims:	1. A compound of Formula (D) having the structure: ##STR00056## wherein: L.sub.a is O or S; Ar is an unsubstituted phenyl; Y is a 4-, 5-, 6-, or 7-membered cycloalkyl ring, or Y is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl; Z is C(.dbd.O), OC(.dbd.O), NHC(.dbd.O), S(.dbd.O).sub.x, or NHS(.dbd.O).sub.x, where x is 2; R.sub.8 is H; R.sub.7 is H, unsubstituted C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, or C.sub.1-C.sub.4alkyl(phenyl); or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, unsubstituted C.sub.1-C.sub.4alkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, or C.sub.1-C.sub.4alkyl(phenyl); or a pharmaceutical acceptable salts thereof. 2. The compound of claim 1, wherein L.sub.a is O. 3. The compound of claim 2, wherein: Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2. 4. The compound of claim 3, wherein: each of R.sub.7 and R.sub.8 is H; or R.sub.7 and R.sub.8 taken together form a bond. 5. A compound of claim 1 selected from among: 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperi- din-1-yl)prop-2-en-1-one; (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)but-2-en-1-one; 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperi- din-1-yl)sulfonylethene; 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperi- din-1-yl)prop-2-yn-1-one; 1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperi- din-1-yl)prop-2-en-1-one; N-((1s,4s)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-y- l)cyclohexyl)acrylamide; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)prop-2-en-1-one; 1-((S)-3-(4-amino-3-(4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyr- rolidin-1-yl)prop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one; 1-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one; and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-(dimethylamino)but-2-en-1-one. 6. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient. 7. The compound of claim 3, wherein: each of R.sub.6 and R.sub.8 is H. 8. The compound of claim 2, wherein the compound has a structure selected from: ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066## ##STR00067## ##STR00068##